ArticleBMC cancer2026
Treatment patterns and survival outcomes of Ewing sarcoma in Ethiopia: a five-year retrospective analysis from a tertiary hospital.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEwing sarcoma is a malignant small round-cell sarcoma of bone or soft tissue that is highly responsive to modern multimodal therapy and considered a highly curable disease in developed countries. However, survival remains poor in developing countries. This study aims to assess treatment patterns and survival outcomes of Ewing sarcoma at Tikur Anbessa Hospital. METHODS AND MATERIALS: We conducted a retrospective study on all patients diagnosed with Ewing sarcoma at Tikur Anbessa Hospital between November 15, 2018, and November 15, 2023. Descriptive statistics and Kaplan-Meier survival analysis were used to analyze the data.
resultThe median age at diagnosis was 19 years, with most of the patients (67.2%) in the age range of 8-25 years. The main modality of treatment for localized disease was chemotherapy combined with surgery, whereas chemotherapy alone was used for metastatic disease. The Kaplan-Meier estimated 1-year and 3-year overall survival (OS) rates for the entire cohort were 96% and 68%, respectively, and the corresponding 1-year and 3-year event-free survival (EFS) rates were 70% and 40%, respectively. A sensitivity analysis treating loss to follow-up as events reduced the 3-year overall survival from 68% to 55% and the 3-year event-free survival from 40 to 33%. The 3-year OS and EFS rates were 89% and 76% for localized disease versus 10% and 0% for metastatic disease. This difference was statistically significant (log-rank p < 0.001). Small tumor size (≤ 8 cm), surgical intervention, and localized stage were associated with statistically significant improvements in OS and EFS, whereas pelvic location was associated with a poorer prognosis.
conclusionEwing sarcoma at our institution mainly affects adolescents and young adults. Survival is poor, especially for metastatic disease, while localized tumors, smaller size, and surgery are associated with better survival. Therefore, early diagnosis and improved multimodal treatment are needed to improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.